Tomita Masatoshi, Aoki Yoichi, Tanaka Kenichi
Division of Obstetrics and Gynecology, Niigata Prefectural Tokamachi Hospital, Niigata, Japan.
Clin Pharmacokinet. 2004;43(8):515-27. doi: 10.2165/00003088-200443080-00002.
Since renal failure itself creates an immunocompromised situation, malignant tumours in haemodialysis patients are increasing due to the prolonged lifespan of these patients. In treating these patients with anticancer agents, dosage reduction is often recommended to avoid adverse drug reactions, particularly for drugs with extensive renal excretion. On the other hand, if an anticancer drug is removed significantly by haemodialysis, dosage increase would be required to ensure adequate therapeutic efficacy. We address in this review the clinical pharmacokinetic aspects of antineoplastic therapy, and the application of pharmacokinetic principles to the adjustment of dosage of anticancer agents in haemodialysis patients.
由于肾衰竭本身会造成免疫功能低下的状况，血液透析患者的恶性肿瘤因这些患者寿命延长而日益增多。在用抗癌药治疗这些患者时，通常建议减少剂量以避免药物不良反应，尤其是对于经肾脏大量排泄的药物。另一方面，如果一种抗癌药能被血液透析显著清除，则需要增加剂量以确保足够的治疗效果。在本综述中，我们探讨了抗肿瘤治疗的临床药代动力学方面，以及药代动力学原理在血液透析患者抗癌药剂量调整中的应用。
